4//SEC Filing
Jones Cecilia 4
Accession 0001439222-25-000104
CIK 0001439222other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 5:56 PM ET
Size
8.9 KB
Accession
0001439222-25-000104
Insider Transaction Report
Form 4
Jones Cecilia
Chief Financial Officer
Transactions
- Sale
Common stock
2025-09-26$36.77/sh−3,651$134,247→ 33,870 total - Exercise/Conversion
Common stock
2025-09-26+7,472→ 37,521 total - Exercise/Conversion
Restricted stock units
2025-09-26−7,472→ 0 total→ Common stock (7,472 underlying)
Footnotes (3)
- [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 26, 2022.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- [F3]The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units vest in three equal annual installments.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001840056
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 5:56 PM ET
- Size
- 8.9 KB